Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Tenacissoside I is a C21 steroidal natural compound derived from the traditional Chinese medicinal herb Marsdenia tenacissima. Tongguan vine, as an important medicinal plant in traditional Chinese medicine, has attracted much attention for its remarkable anti-inflammatory, anti-tumor, and immunomodulatory effects. As one of its main active ingredients, Tamguan I, has shown broad application potential in pharmacological research in recent years. Its unique chemical structure and multi-target regulatory capability make it a potential candidate drug for anti-inflammatory disease treatment. This paper systematically reviews the chemical structure and physicochemical properties of Tamguan Tengin I, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and clinical application prospects, aiming to provide theoretical basis and research directions for subsequent basic research and drug development.

Chemical structure and physicochemical properties

Tycosin I belongs to the C21 steroid glycoside class, with the molecular formula C_41H_62O_16 and a molecular weight of 814.9660. Its structural core is a typical steroid skeleton, supplemented by multiple glycosidic groups, giving it high polarity and complex spatial conformations. The LogP value is 3.3123, indicating moderate hydrophobicity, which facilitates cell membrane penetration without excessive hydrophobicity and affecting solubility. The topological pole surface area (TPSA) is 178.0400, indicating that the molecule contains a large number of polar groups, especially hydroxyl and glycoside groups, enhancing its ability to bind to biological macromolecules.

Low water solubility (0.0082 mg/mL) suggests that the solubility of Clearance I in water is limited, which may affect its bioavailability and the choice of administration method. The blood-brain barrier has a relatively low penetration capacity, indicating limited distribution in the central nervous system, which may reduce CNS side effects. The hERG channel inhibition test was negative, indicating a lower risk of cardiotoxicity. The Ames-induced mutagenic test was 0.0, indicating a low genotoxicity risk and high safety.

Plant Origins and Extraction Methods

Testicin I is mainly found throughout the whole plant of Marsdenia tenacissima, with higher concentrations in dried stems and leaves. Marsdenia tenacissima, belonging to the Apocynaceae family, is widely distributed in southern China and Southeast Asia, and is the main source plant of the traditional Chinese medicine 'Tongguan vine.' Since ancient times, this plant has been used to treat asthma, rheumatoid arthritis, tumors, and other diseases.

Common methods for extracting Clearance Tengsin I include solvent extraction, column chromatography separation, and high-performance liquid chromatography (HPLC) purification. Generally, ethanol or methanol is used as the extraction solvent, and crude extracts are obtained by reflux extraction. Afterwards, silica gel column chromatography or reversed-phase C18 columns were used for separation and purification, and purity and structure were confirmed by HPLC and mass spectrometry. In recent years, ultrasound-assisted extraction and microwave-assisted extraction technologies have also been applied to improve extraction efficiency and purity. In addition, enzymatic hydrolysis and membrane separation technologies show potential in optimizing extraction processes, helping to achieve large-scale production.

Pharmacological activity research

Pharmacological activity studies of Mettosin I have mainly focused on its anti-inflammatory effects. Multiple in vitro and in vivo experiments have shown that Ascendant Tengsin I can significantly inhibit the production of inflammatory mediators and activate inflammatory signaling pathways, demonstrating good anti-inflammatory effects.

Anti-inflammatory activity

Tamsinosin I regulates various inflammation-related factors, inhibiting the expression of pro-inflammatory cytokines such as IL-6 and TNF-α, thereby reducing inflammatory responses. In animal models, transceiving vinigine I significantly reduced edema and cellular infiltration at the site of inflammation, lessening tissue damage. Additionally, it inhibits inflammation-related enzymes such as cyclooxygenase (PTGS1, PTGS2) and induced nitric oxide synthase (NOS2), reducing excessive production of prostaglandins and nitric oxide.

Immune regulation

Tamguan Tengin I can also regulate immune cell function, affect the activation status of macrophages and lymphocytes, and promote the maintenance of immune homeostasis. Its regulatory effect on inflammasomes (such as CASP1) helps suppress inflammatory cascades, reducing apoptosis and tissue damage.

Other pharmacological effects

Although anti-inflammatory is the main research focus for trans-tasin I, some studies have indicated that it has certain antitumor activity, possibly inhibiting tumor cell proliferation and migration by regulating the STAT3 signaling pathway. Additionally, regulation of pain receptors TRPV1 and TRPA1 suggests potential application value in alleviating inflammatory pain.

Mechanism of action and molecular targets

The anti-inflammatory effect of Tamguan I's response involves multiple signaling pathways and multiple molecular targets, demonstrating its multi-target and multi-pathway coordinated regulation.

1. IL-6/STAT3 pathway

IL-6, as a key pro-inflammatory cytokine, promotes inflammatory responses and immune regulation by activating the STAT3 signaling pathway. Tamantengin I can inhibit IL-6 secretion and STAT3 phosphorylation, blocking the transcription expression of downstream pro-inflammatory genes and thereby reducing inflammatory responses.

2. NF-κB signaling pathway

NF-κB is a core transcription factor in inflammatory responses, regulating the expression of various inflammatory mediators. Tycosin I exerts anti-inflammatory effects by inhibiting NF-κB activation, reducing the production of pro-inflammatory cytokines (such as TNF-α, IL-6) and inflammatory enzymes (PTGS2, NOS2).

3. Regulation of inflammasome CASP1

CASP1, as a key component of inflammasomes, is involved in the maturation and release of pro-inflammatory cytokines. Testigine I can inhibit CASP1 activity, reduce the release of inflammatory factors such as IL-1β, and lower inflammatory cascade reactions.

4. Regulation of TRPV1 and TRPA1 receptors

TRPV1 and TRPA1 are ion channels that sense inflammatory pain; trans-testicular I alleviates inflammation-related pain and neuroinflammation by modulating these two targets.

5. Cyclooxygenase (PTGS1/PTGS2) and nitric oxide synthase (NOS2)

Tagamisin I inhibits the expression of PTGS1 and PTGS2, reduces prostaglandin synthesis, and relieves inflammation and pain. At the same time, it inhibits NOS2, reduces excess nitric oxide production, and alleviates oxidative stress and inflammatory damage.

In summary, Tuanguan Tengin I regulates the inflammatory signaling network through multi-target synergistic action, demonstrating significant anti-inflammatory effects.

Druggability evaluation and pharmacokinetics

The druggability evaluation of Tamguan Tengin I shows it has certain drug development potential, but also faces certain challenges.

Physicochemical properties of the drug

A larger molecular weight (814.9660) and higher polarity (TPSA 178.0400) may limit its oral absorption and ability to penetrate cell membranes. The LogP value of 3.3123 is moderate, which helps balance lipid and water solubility, but its low water solubility (0.0082 mg/mL) may affect bioavailability.

Safety assessment

The hERG channel inhibition test was negative, and the Ames mutagenic test was 0.0, indicating that passing through Tengin I carries low risk of cardiotoxicity and genotoxicity, and its safety is relatively good.

Pharmacokinetic characteristics

Currently, pharmacokinetic studies on Gateway I are limited; preliminary data indicate its low blood-brain barrier penetration capacity, limiting its distribution in the central nervous system. Its metabolic pathways and half-life in vivo still require further systematic research to guide dosage formulation design and administration protocol optimization.

Drug delivery routes and formulation development

Given their poor water solubility, the bioavailability of oral formulations may be limited, so new formulation technologies such as nanocarriers, liposomes, or solid dispersions should be considered to improve solubility and absorption rates. Intravenous or local administration may also be effective approaches.

Prospects and outlooks for clinical applications

As a multi-target anti-inflammatory natural product, Tagtoguan I has broad clinical application prospects. Its potential therapeutic effects in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and certain autoimmune diseases are worth further exploration. In addition, adjuvant therapy for inflammation-related tumors also holds certain application value.

Future research should focus on the following aspects:

1. Systematic pharmacokinetic and toxicological studies: clarify the absorption, distribution, metabolism, and excretion characteristics of Clearance Tengsin I in the body, and assess the safety of long-term medication.
2. In-depth mechanism analysis: Using multi-omics techniques and molecular biology methods, the panoramic signal network of its effects is revealed, uncovering new potential targets.
3. Formulation innovation and delivery optimization: Developing efficient delivery systems to improve bioavailability and targeting, overcoming limitations of poor water solubility.
4. Preclinical and clinical trials: Conduct animal model validation and early clinical studies to evaluate efficacy and safety, and promote clinical translation.
5. Combination therapy strategies: Explore the synergistic effects of Tamsinosin I with existing anti-inflammatory drugs or immunomodulators to enhance treatment outcomes and reduce side effects.

Conclusion

Toxic Glycoside I, a C21 steroid glycoside natural product rich in Marsdenia tenacissima with significant anti-inflammatory activity, demonstrates unique advantages in regulating inflammatory responses through multiple targets and pathways. Its excellent safety profile and potential clinical value make it a research hotspot in natural product pharmacology and new drug development. Although research on its pharmacokinetics and clinical efficacy is still in its early stages, with continuous advances in extraction and purification technologies and modern drug development methods, Tianguan I is expected to become a novel candidate drug for anti-inflammatory disease treatment. Future systematic research and clinical validation will lay a solid foundation for its clinical translation, promoting its widespread application in the field of natural medicines.